Testing effectiveness (Phase 2)Ended earlyNCT00215540
What this trial is testing
SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.
Who this might be right for
Respiratory Distress Syndrome, NewbornPremature BirthBronchopulmonary Dysplasia
Windtree Therapeutics 136